MedTrace Logo

Pasireotide in Hyperinsulinemic Hypoglycemia

NCT03053284 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-05-14

No results posted yet for this study

Summary

This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.

Conditions

  • Congenital Hyperinsulinism
  • Insulinoma
  • Hyperinsulinism

Interventions

DRUG

Pasireotide 0.6Mg Solution for Injection

Pasireotide 0.6Mg Solution for Injection will be given once per study visit

DRUG

Saline Solution

Saline Solution injection will be given once per study visit

Sponsors & Collaborators

Principal Investigators

  • Erika Brutsaert, M.D., M.P.H. · Montefiore Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2018-01-31
Completion
2018-04-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03053284 on ClinicalTrials.gov